In what can only be called a barrage, the Washington Post trained its guns on the Myriad case and gene patents. The shock and awe campaign's opening salvo was an Op Ed piece titled "Who owns your DNA? Not who you think." in the print edition, and more directly on line as "The Supreme Court should invalidate the patent on human DNA." Jeffrey Rosenfeld and Christopher Mason, holding PhD's from NYU and Yale, respectively, who are professors of genomics at New Jersey and Cornell Medical Schools, respectively. were the authors. They conclude, "It is imperative that the Supreme Court invalidate Myriad’s patent, defend genomic liberty and make clear that one’s genes belong to that person alone."
Then, in an editorial timed to coincide with the oral arguments in the case on April 15, 2013, the Post fired, "Patents on Human DNA need Congress's input."
The next day, two thirds of A2 rang out with commentary by Dana Milbank and straight reportage by Robert Barnes. I have only one comment to make, and it's addressed to Dana Milbank: While I agree with your conclusion wholeheartedly, shame on you for making fun of Justice Sotomayor - we need the vote!
Wednesday, April 17, 2013
Tuesday, April 16, 2013
Transcript
Myriad Supreme Court Transcript:
http://www.supremecourt.gov/oral_arguments/argument_transcripts/12-398-amc7.pdf
http://www.supremecourt.gov/oral_arguments/argument_transcripts/12-398-amc7.pdf
Sunday, April 14, 2013
Interesting Poll:
In anticipation of the Myriad hearing tomorrow the IPO (see pages 69-72 of my book "Other Peoples Bodies.") is having a webinar on the case on Wednesday, April 17. On the panel will be be our own, Prof. Joshua Sarnoff, along with two bio-patent techies.
A previous webinar was held on the Prometheus case, in which the SCOTUS unanimously struck down a patent on so-called "personalized medicine." The Myriad and Prometheus cases are closely linked.
In the wake of the previous webinar, the guiding hand behind it, Pamela Sherrid, conducted a poll with some not so surprising results: 75% of the patent professionals responding said the SCOTUS got the law wrong; 66% said they could get around the decision by clever claim drafting. Finally, the poll asked several questions about the Myriad case. Here's the surprise: 44% said the decision would be the same, with 41% saying the Court would take the DOJ position (See page 57 of "OPB") and, not surprisingly, only 15% saying all claims would be invalidated. The poll is located at:
http://ipchat.biz/prometheuspoll.html
In anticipation of the Myriad hearing tomorrow the IPO (see pages 69-72 of my book "Other Peoples Bodies.") is having a webinar on the case on Wednesday, April 17. On the panel will be be our own, Prof. Joshua Sarnoff, along with two bio-patent techies.
A previous webinar was held on the Prometheus case, in which the SCOTUS unanimously struck down a patent on so-called "personalized medicine." The Myriad and Prometheus cases are closely linked.
In the wake of the previous webinar, the guiding hand behind it, Pamela Sherrid, conducted a poll with some not so surprising results: 75% of the patent professionals responding said the SCOTUS got the law wrong; 66% said they could get around the decision by clever claim drafting. Finally, the poll asked several questions about the Myriad case. Here's the surprise: 44% said the decision would be the same, with 41% saying the Court would take the DOJ position (See page 57 of "OPB") and, not surprisingly, only 15% saying all claims would be invalidated. The poll is located at:
http://ipchat.biz/prometheuspoll.html
Friday, February 22, 2013
ALDF Revisited
A new opportunity has arisen to overturn ALDF v Quigg, the case testing the validity of patents on all non-human animals.
Prolume v Gentarget et al.is outlined below:
Infringement
|
Court : U.S. District Court for the Southern District of California
|
Presided by: William Q. Hayes
|
Civil Action No: 3:13-cv-00130-WQH-BLM
|
Defendant(s) :
1. Gentarget, Inc.
2. Genprice, Inc.
3. Amsbio LLC
4. BST Scientific PTE LTD
5. Gentaur Molecular Products BVBA
6. Filgen Biosciences, Inc.
7. Does 1 through 10, Inclusive
|
Plaintiff(s) :
Prolume, LTD. — represented by
Law Offices of Philip J Kaplan; Los Angeles, CA Attorneys: Philip Jeremy Kaplan |
Patent(s) in Suit :
|
|
Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent
by Bryan et. al. |
|
Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins
by Bryan et. al. |
The lawsuit reeks of the the "indicia of extortion."
Additionally since the patents claim animal genes (aquatic life) a defense might be the invalidity of patents for the reasons argued by ALDF against then-Commissioner Donald Quigg, supporting the Patent Office. For details see the post on my blog: (http://www.koshergoldfish.com/ethics_of_biotechnology.html)
"Other Peoples Bodies."
GenTarget Inc, 6640 Lusk Blvd. Suite A107, San Diego, USA(858)678-8683
Tuesday, February 19, 2013
Interesting SCOTUS Blog post
http://www.scotusblog.com/2013/02/nothing-under-the-sun-that-is-made-of-man/
The author concludes:
" In any case, if the law’s prior treatment of human-related inventions is a reliable guide, it is likely that human gene patents will soon be history."
The author concludes:
" In any case, if the law’s prior treatment of human-related inventions is a reliable guide, it is likely that human gene patents will soon be history."
Watson Brief before the Supreme Court
http://www.wileyrein.com/newsroom.cfm?sp=newsreleases&id=810
The brief is at the end of the article.
The brief is at the end of the article.
Oral Argument set for Monday, April 15, 2013
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to:
Posts (Atom)
